Skip to main content
SpringerLink
Log in

Antipsychotic Polypharmacy in Schizophrenia. How to Counteract This Common Practice?

  • Chapter
  • First Online:
Polypharmacy in Psychiatry Practice, Volume II

  • 1155 Accesses

Abstract

Antipsychotic polypharmacy (using multiple antipsychotics simultaneously) in schizophrenia appears to be a common practice in the real world. However, it has been a practice with substantial debate for its possible pros and cons. In this section, we systematically review clinical evidence on antipsychotic polypharmacy in schizophrenia. We first focus on the prevalence of antipsychotic polypharmacy in schizophrenia in the real-world clinical settings, to highlight the fact that it is becoming a frequent reality. Next, we discuss potential mechanisms that lead to such a controversial practice. Then, meta-analyses and systematic reviews that addressed the usefulness of antipsychotic polypharmacy in schizophrenia are qualitatively assessed.

The results of this critical appraisal on the currently available evidence indicate that usefulness of antipsychotic polypharmacy in schizophrenia has been a focus of extensive research. However, there are practically too many possible combinations to be evaluated with each antipsychotic dosage also in mind. Evidence on antipsychotic polypharmacy currently remains equivocal at best even for polypharmacy involving clozapine; it is all the more questionable for other mode of antipsychotic combination therapy. Moreover, there has been no study that evaluated antipsychotic polypharmacy in reference with other various augmentation strategies that may potentially be effective.

While a possibility cannot be denied for clinical usefulness of some mode of antipsychotic combination therapy in schizophrenia in general (e.g., combining prolactin-raising or metabolically problematic antipsychotics with more benign agents) or on an individual basis (i.e., for treatment-resistant schizophrenia), the currently available evidence supports the notion that prescribers should remain very conservative in resorting to antipsychotic polypharmacy. In other words, physicians should keep in mind the very basic of pharmacotherapy in every field of medicine; medications should be simple at least at early stages of treatment unless evidence unequivocally points to the contrary.

An effort will be made to synthesize the currently available evidence to be translated into future directions on this critically relevant topic. Further, potential strategies to counteract antipsychotic polypharmacy in schizophrenia are discussed in detail. More work is clearly indicated for this important issue that will remain a matter of hot debate for the years to come.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Abbreviations

BPRS:

Brief Psychiatric Rating Scale

CGI:

Clinical Global Impression

EPS:

Extrapyramidal symptoms

FGAs:

First-generation antipsychotics

GAF:

Global Assessment of Functioning

PANSS:

Positive and Negative Syndrome Scale

SGAs:

Second-generation antipsychotics

TRS:

Treatment resistant schizophrenia

References

  1. Suzuki T, Uchida H, Watanabe K et al (2007) How effective is it to sequentially switch among Olanzapine, Quetiapine and Risperidone?—a randomized, open-label study of algorithm-based antipsychotic treatment to patients with symptomatic schizophrenia in the real-world clinical setting. Psychopharmacology (Berl) 195(2):285–295

    Article  CAS  Google Scholar 

  2. Moore TA, Buchanan RW, Buckley PF et al (2007) The Texas medication algorithm project antipsychotic algorithm for schizophrenia: 2006 update. J Clin Psychiatry 68(11):1751–1762

    Article  PubMed  CAS  Google Scholar 

  3. Suzuki T, Remington G, Mulsant BH et al (2011) Treatment resistant schizophrenia and response to antipsychotics: a review. Schizophr Res 133(1–3):54–62

    Article  PubMed  Google Scholar 

  4. Bolstad A, Andreassen OA, Røssberg JI et al (2011) Previous hospital admissions and disease severity predict the use of antipsychotic combination treatment in patients with schizophrenia. BMC Psychiatry 11:126

    Article  PubMed  Google Scholar 

  5. Dolder CR, McKinsey J (2011) Antipsychotic polypharmacy among patients admitted to a geriatric psychiatry unit. J Psychiatr Pract 17(5):368–374

    Article  PubMed  Google Scholar 

  6. Li C, Mittal D, Owen RR (2011) Impact of patients’ preexisting metabolic risk factors on the choice of antipsychotics by office-based physicians. Psychiatr Serv 62(12):1477–1484

    Article  PubMed  Google Scholar 

  7. Misawa F, Shimizu K, Fujii Y et al (2011) Is antipsychotic polypharmacy associated with metabolic syndrome even after adjustment for lifestyle effects?: a cross-sectional study. BMC Psychiatry 11:118

    Article  PubMed  Google Scholar 

  8. Santone G, Bellantuono C, Rucci P et al (2011) Patient characteristics and process factors associated with antipsychotic polypharmacy in a nationwide sample of psychiatric inpatients in Italy. Pharmacoepidemiol Drug Saf 20(5):441–449

    Article  PubMed  Google Scholar 

  9. Wu CS, Lin YJ, Liu SK (2011) Benzodiazepine use among patients with schizophrenia in Taiwan: a nationwide population-based survey. Psychiatr Serv 62(8):908–914

    Article  PubMed  Google Scholar 

  10. Xiang YT, Wang CY, Si TM et al (2012) Antipsychotic polypharmacy in inpatients with schizophrenia in Asia (2001–2009). Pharmacopsychiatry 45(1):7–12

    Google Scholar 

  11. An FR, Xiang YT, Wang CY et al (2010) Change of psychotropic drug prescription for schizophrenia in a psychiatric institution in Beijing, China between 1999 and 2008. Int J Clin Pharmacol Ther 48(4):270–274

    PubMed  Google Scholar 

  12. Constantine RJ, Andel R, Tandon R (2010) Trends in adult antipsychotic polypharmacy: progress and challenges in Florida’s Medicaid program. Community Ment Health J 46(6):523–530

    Article  PubMed  Google Scholar 

  13. Nielsen J, le Quach P, Emborg C et al (2010) 10-year trends in the treatment and outcomes of patients with first-episode schizophrenia. Acta Psychiatr Scand 122(5):356–366

    Article  PubMed  Google Scholar 

  14. Procyshyn RM, Honer WG, Wu TK et al (2010) Persistent antipsychotic polypharmacy and excessive dosing in the community psychiatric treatment setting: a review of medication profiles in 435 Canadian outpatients. J Clin Psychiatry 71(5):566–573

    Article  PubMed  CAS  Google Scholar 

  15. Ramos-Ríos R, Arrojo-Romero M, Paz-Silva E et al (2010) QTc interval in a sample of long-term schizophrenia inpatients. Schizophr Res 116(1):35–43

    Article  PubMed  Google Scholar 

  16. Ranceva N, Ashraf W, Odelola D (2010) Antipsychotic polypharmacy in outpatients at Birch Hill Hospital: incidence and adherence to guidelines. J Clin Pharmacol 50(6):699–704

    Article  PubMed  CAS  Google Scholar 

  17. Kroken RA, Johnsen E, Ruud T et al (2009) Treatment of schizophrenia with antipsychotics in Norwegian emergency wards, a cross-sectional national study. BMC Psychiatry 9:24

    Article  PubMed  Google Scholar 

  18. Huang MC, Lu ML, Tsai CJ et al (2009) Prevalence of metabolic syndrome among patients with schizophrenia or schizoaffective disorder in Taiwan. Acta Psychiatr Scand 120(4):274–280

    Article  PubMed  Google Scholar 

  19. McKean A, Vella-Brincat J (2009) Audit of antipsychotic polypharmacy in Christchurch. Australas Psychiatry 17(4):336–337

    Article  PubMed  Google Scholar 

  20. Wheeler A (2009) Explicit versus implicit review to explore combination antipsychotic prescribing. J Eval Clin Pract 15(4):685–691

    Article  PubMed  Google Scholar 

  21. Yu AP, Ben-Hamadi R, Birnbaum HG et al (2009) Comparing the treatment patterns of patients with schizophrenia treated with olanzapine and quetiapine in the Pennsylvania Medicaid population. Curr Med Res Opin 25(3):755–764

    Article  PubMed  CAS  Google Scholar 

  22. Ahn J, McCombs JS, Jung C et al (2008) Classifying patients by antipsychotic adherence patterns using latent class analysis: characteristics of nonadherent groups in the California Medicaid (Medi-Cal) program. Value Health 11(1):48–56

    Article  PubMed  Google Scholar 

  23. Connolly A, Taylor D (2008) Ethnicity and quality of antipsychotic prescribing among in-patients in south London. Br J Psychiatry 193(2):161–162

    Article  PubMed  Google Scholar 

  24. Koen L, Magni P, Niehaus DJ, le Roux A (2008) Antipsychotic prescription patterns in Xhosa patients with schizophrenia or schizoaffective disorder. Afr J Psychiatry (Johannesbg) 11(4):287–290

    CAS  Google Scholar 

  25. Lass J, Männik A, Bell JS (2008) Pharmacotherapy of first episode psychosis in Estonia: comparison with national and international treatment guidelines. J Clin Pharm Ther 33(2):165–173

    Article  PubMed  CAS  Google Scholar 

  26. Lerma-Carrillo I, de Pablo Brühlmann S, del Pozo ML et al (2008) Antipsychotic polypharmacy in patients with schizophrenia in a brief hospitalization unit. Clin Neuropharmacol 31(6):319–332

    Article  PubMed  CAS  Google Scholar 

  27. Pickar D, Vinik J, Bartko JJ (2008) Pharmacotherapy of schizophrenic patients: preponderance of off-label drug use. PLoS One 3(9):e3150

    Article  PubMed  Google Scholar 

  28. Taylor M, Shajahan P, Lawrie SM (2008) Comparing the use and discontinuation of antipsychotics in clinical practice: an observational study. J Clin Psychiatry 69(2):240–245

    Article  PubMed  Google Scholar 

  29. Wheeler A, Humberstone V, Robinson E (2008) Ethnic comparisons of antipsychotic use in schizophrenia. Aust N Z J Psychiatry 42(10):863–873

    Article  PubMed  Google Scholar 

  30. Lieberman JA, Stroup TS, McEvoy JP et al (2005) Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 353(12):1209–1223

    Article  PubMed  CAS  Google Scholar 

  31. Kahn RS, Fleischhacker WW, Boter H et al (2008) Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomized clinical trial. Lancet 371(9618):1085–1097

    Article  PubMed  CAS  Google Scholar 

  32. Pringsheim T, Lam D, Tano DS et al (2011) The pharmacoepidemiology of antipsychotics for adults with schizophrenia in Canada, 2005 to 2009. Can J Psychiatry 56(10):630–634

    PubMed  Google Scholar 

  33. Remington G, Saha A, Chong SA et al (2005) Augmentation strategies in clozapine-resistant schizophrenia. CNS Drugs 19(10):843–872

    Article  PubMed  CAS  Google Scholar 

  34. Mojtabai R, Olfson M (2010) National trends in psychotropic medication polypharmacy in office-based psychiatry. Arch Gen Psychiatry 67(1):26–36

    Article  PubMed  Google Scholar 

  35. Baandrup L, Allerup P, Nordentoft M et al (2010) Exploring regional variation in antipsychotic coprescribing practice: a Danish questionnaire survey. J Clin Psychiatry 71(11):1457–1464

    Article  PubMed  Google Scholar 

  36. Correll CU, Shaikh L, Gallego JA et al (2011) Antipsychotic polypharmacy: a survey study of prescriber attitudes, knowledge and behavior. Schizophr Res 131(1–3):58–62

    Google Scholar 

  37. Tsutsumi C, Uchida H, Suzuki T et al (2011) The evolution of antipsychotic switch and polypharmacy in natural practice—a longitudinal perspective. Schizophr Res 130(1–3):40–46

    Article  PubMed  Google Scholar 

  38. Kreyenbuhl J, Marcus SC, West JC et al (2007) Adding or switching antipsychotic medications in treatment-refractory schizophrenia. Psychiatr Serv 58(7):983–990

    Article  PubMed  Google Scholar 

  39. Baandrup L, Sørensen J, Lublin H, Nordentoft M, Glenthoj B (2012) Association of anti­psychotic polypharmacy with health service cost: a register-based cost analysis. Eur J Health Econ 13(3):355–363

    Google Scholar 

  40. Kreyenbuhl JA, Valenstein M, McCarthy JF et al (2007) Long-term antipsychotic polypharmacy in the VA health system: patient characteristics and treatment patterns. Psychiatr Serv 58(4):489–495

    Article  PubMed  Google Scholar 

  41. Kessing LV, Thomsen AF, Mogensen UB et al (2010) Treatment with antipsychotics and the risk of diabetes in clinical practice. Br J Psychiatry 197(4):266–271

    Article  PubMed  Google Scholar 

  42. Citrome L (2012) A systematic review of meta-analyses of the efficacy of oral atypical anti­psychotics for the treatment of adult patients with schizophrenia. Expert Opin Pharmacother 13(11):1545-1573. doi:10.1517/14656566.2011.626769

    Google Scholar 

  43. Pandurangi AK, Dalkilic A (2008) Polypharmacy with second-generation antipsychotics: a review of evidence. J Psychiatr Pract 14(6):345–367

    Article  PubMed  Google Scholar 

  44. Stahl SM, Grady MM (2004) A critical review of atypical antipsychotic utilization: comparing monotherapy with polypharmacy and augmentation. Curr Med Chem 11(3):313–327

    Article  PubMed  CAS  Google Scholar 

  45. Porcelli S, Balzarro B, Serretti A (2012) Clozapine resistance: augmentation strategies. Eur Neuropsychopharmacol 22(3):165–182

    Google Scholar 

  46. Taylor DM, Smith L, Gee SH, Nielsen J (2012) Augmentation of clozapine with a second antipsychotic – a meta-analysis. Acta Psychiatr Scand 125(1):15–24. doi:10.1111/j.1600-0447.2011.01792.x

    Google Scholar 

  47. Wang J, Omori IM, Fenton M, Soares B (2010) Sulpiride augmentation for schizophrenia. Cochrane Database Syst Rev doi:10.1002/14651858.CD008125.pub2

  48. Barbui C, Signoretti A, Mulè S et al (2009) Does the addition of a second antipsychotic drug improve clozapine treatment? Schizophr Bull 35(2):458–468

    Article  PubMed  Google Scholar 

  49. Cipriani A, Boso M, Barbui C (2009) Clozapine combined with different antipsychotic drugs for treatment resistant schizophrenia. Cochrane Database Syst Rev doi:10.1002/14651858.CD006324.pub2

  50. Correll CU, Rummel-Kluge C, Corves C et al (2009) Antipsychotic combinations vs. monotherapy in schizophrenia: a meta-analysis of randomized controlled trials. Schizophr Bull 35(2):443–457

    Article  PubMed  Google Scholar 

  51. Taylor DM, Smith L (2009) Augmentation of clozapine with a second antipsychotic—a meta-analysis of randomized, placebo-controlled studies. Acta Psychiatr Scand 119(6):419–425

    Article  PubMed  CAS  Google Scholar 

  52. Paton C, Whittington C, Barnes TR (2007) Augmentation with a second antipsychotic in patients with schizophrenia who partially respond to clozapine: a meta-analysis. J Clin Psychopharmacol 27(2):198–204

    Article  PubMed  CAS  Google Scholar 

  53. Barbui C, Accordini S, Nosè M et al (2011) Aripiprazole versus haloperidol in combination with clozapine for treatment-resistant schizophrenia in routine clinical care: a randomized, controlled trial. J Clin Psychopharmacol 31(3):266–273

    Article  PubMed  CAS  Google Scholar 

  54. Suzuki T, Uchida H, Watanabe K et al (2011) Factors associated with response to clozapine in schizophrenia: a review. Psychopharmacol Bull 44(1):32–60

    PubMed  Google Scholar 

  55. Chan J, Sweeting M (2007) Review: combination therapy with non-clozapine atypical antipsychotic medication: a review of current evidence. J Psychopharmacol 21(6):657–664

    Article  PubMed  CAS  Google Scholar 

  56. Zink M (2005) Augmentation of olanzapine in treatment-resistant schizophrenia. J Psychiatry Neurosci 30(6):409–415

    PubMed  Google Scholar 

  57. Suzuki T, Uchida H, Watanabe K et al (2008) Effectiveness of antipsychotic polypharmacy for patients with treatment refractory schizophrenia: an open-label trial of olanzapine plus risperidone for those who failed to respond to a sequential treatment with olanzapine, quetiapine and risperidone. Hum Psychopharmacol 23(6):455–463

    Article  PubMed  CAS  Google Scholar 

  58. Henderson DC, Kunkel L, Nguyen DD et al (2006) An exploratory open-label trial of aripiprazole as an adjuvant to clozapine therapy in chronic schizophrenia. Acta Psychiatr Scand 113(2):142–147

    Article  PubMed  CAS  Google Scholar 

  59. Ziegenbein M, Wittmann G, Kropp S (2006) Aripiprazole augmentation of clozapine in treatment-resistant schizophrenia: a clinical observation. Clin Drug Invest 26(3):117–124

    Article  CAS  Google Scholar 

  60. Karunakaran K, Tungaraza TE, Harborne GC (2007) Is clozapine-aripiprazole combination a useful regime in the management of treatment-resistant schizophrenia? J Psychopharmacol 21(4):453–456

    Article  PubMed  CAS  Google Scholar 

  61. Chang JS, Ahn YM, Park HJ et al (2008) Aripiprazole augmentation in clozapine-treated patients with refractory schizophrenia: an 8-week, randomized, double-blind, placebo-controlled trial. J Clin Psychiatry 69(5):720–731

    Article  PubMed  CAS  Google Scholar 

  62. Fleischhacker WW, Heikkinen ME, Olié JP et al (2010) Effects of adjunctive treatment with aripiprazole on body weight and clinical efficacy in schizophrenia patients treated with clozapine: a randomized, double-blind, placebo-controlled trial. Int J Neuropsychopharmacol 13(8):1115–1125

    Article  PubMed  CAS  Google Scholar 

  63. Muscatello MR, Bruno A, Pandolfo G et al (2011) Effect of aripiprazole augmentation of clozapine in schizophrenia: a double-blind, placebo-controlled study. Schizophr Res 127(1–3):93–99

    Article  PubMed  Google Scholar 

  64. Tschoner A, Engl J, Laimer M et al (2007) Metabolic side effects of antipsychotic medication. Int J Clin Pract 61(8):1356–1370

    Article  PubMed  CAS  Google Scholar 

  65. Klemp M, Tvete IF, Skomedal T et al (2011) A review and bayesian meta-analysis of clinical efficacy and adverse effects of 4 atypical neuroleptic drugs compared with haloperidol and placebo. J Clin Psychopharmacol 31(6):698–704

    Article  PubMed  CAS  Google Scholar 

  66. Zink M, Knopf U, Henn FA et al (2004) Combination of clozapine and amisulpride in treatment-resistant schizophrenia—case reports and review of the literature. Pharmacopsychiatry 37(1):26–31

    Article  PubMed  CAS  Google Scholar 

  67. Kreinin A, Novitski D, Weizman A (2006) Amisulpride treatment of clozapine-induced hyper salivation in schizophrenia patients: a randomized, double-blind, placebo-controlled cross-over study. Int Clin Psychopharmacol 21(2):99–103

    Article  PubMed  Google Scholar 

  68. Godleski LS, Kerler R, Barber JW et al (1989) Multiple versus single antipsychotic drug treatment in chronic psychosis. J Nerv Ment Dis 177(11):686–689

    Article  PubMed  CAS  Google Scholar 

  69. Suzuki T, Uchida H, Tanaka KF et al (2004) Revising polypharmacy to a single antipsychotic regimen for patients with chronic schizophrenia. Int J Neuropsychopharmacol 7(2):133–142

    Article  PubMed  CAS  Google Scholar 

  70. Essock SM, Schooler NR, Stroup TS et al (2011) Effectiveness of switching from antipsychotic polypharmacy to monotherapy. Am J Psychiatry 168(7):702–708

    Article  PubMed  Google Scholar 

  71. Takeuchi H, Suzuki T, Uchida H et al (2008) A randomized, open-label comparison of 2 switching strategies to aripiprazole treatment in patients with schizophrenia: add-on, wait, and tapering of previous antipsychotics versus add-on and simultaneous tapering. J Clin Psychopharmacol 28(5):540–543

    Article  PubMed  CAS  Google Scholar 

  72. Suzuki T, Uchida H, Takeuchi H et al (2009) Augmentation of atypical antipsychotics with valproic acid. An open-label study for most difficult patients with schizophrenia. Hum Psychopharmacol 24(8):628–638

    Article  PubMed  CAS  Google Scholar 

  73. Thompson A, Sullivan SA, Barley M et al (2008) The DEBIT trial: an intervention to reduce antipsychotic polypharmacy prescribing in adult psychiatry wards—a cluster randomized controlled trial. Psychol Med 38(5):705–715

    Article  PubMed  CAS  Google Scholar 

  74. Mistler LA, Mellman TA, Drake RE (2009) A pilot study testing a medication algorithm to reduce polypharmacy. Qual Saf Health Care 18(1):55–58

    Article  PubMed  CAS  Google Scholar 

  75. Goh YL, Seng KH, Chuan AS et al (2011) Reducing antipsychotic polypharmacy among psychogeriatric and adult patients with chronic schizophrenia. Perm J 15(2):52–56

    PubMed  Google Scholar 

  76. Laska E, Siegel C, Simpson G (1980) Automated review system for orders of psychotropic drugs. Arch Gen Psychiatry 37(7):824–827

    Article  PubMed  CAS  Google Scholar 

  77. Hazra M, Uchida H, Sproule B et al (2011) Impact of feedback from pharmacists in reducing antipsychotic polypharmacy in schizophrenia. Psychiatry Clin Neurosci 65(7):676–678

    Article  PubMed  Google Scholar 

  78. Tucker WM (2007) When less is more: reducing the incidence of antipsychotic polypharmacy. J Psychiatr Pract 13(3):202–204

    Article  PubMed  Google Scholar 

  79. Robst J (2012) Changes in antipsychotic medication use after implementation of a Medicaid mental health carve-out in the US. PharmacoEconomics 30(5):387–396

    Article  PubMed  Google Scholar 

  80. Baandrup L, Allerup P, Lublin H et al (2010) Evaluation of a multifaceted intervention to limit excessive antipsychotic co-prescribing in schizophrenia out-patients. Acta Psychiatr Scand 122(5):367–374

    Article  PubMed  Google Scholar 

  81. Thompson A, Sullivan S, Barley M et al (2010) Effectiveness of a cognitive behavioral workbook for changing beliefs about antipsychotic polypharmacy: analysis from a cluster randomized controlled trial. J Eval Clin Pract 16(3):520–528

    PubMed  Google Scholar 

  82. Finnerty MT, Kealey E, Leckman-Westin E et al (2011) Long-term impact of web-based tools, leadership feedback, and policies on inpatient antipsychotic polypharmacy. Psychiatr Serv 62(10):1124–1126

    Article  PubMed  Google Scholar 

  83. Barnes TR, Paton C (2011) Improving prescribing practice in psychiatry: the experience of the Prescribing Observatory for Mental Health (POMH-UK). Int Rev Psychiatry 23(4):328–335

    Article  PubMed  Google Scholar 

  84. Bebawy M, Chetty M (2008) Differential pharmacological regulation of drug efflux and pharmacoresistant schizophrenia. Bioessays 30(2):183–188

    Article  PubMed  Google Scholar 

  85. Gallego JA, Bonetti J, Zhang J, Kane JM, Correll CU (2012) Prevalence and correlates of anti­psychotic polypharmacy: a systematic review and meta-regression of global and regional trends from the 1970s to 2009. Schizophr Res 138(1):18–28. doi:10.1016/j.schres.2012.03.018

    Google Scholar 

  86. Suzuki T (2011) An importance of dose in antipsychotic combination therapy for schizophrenia. J Clin Psychopharmacol 31(3):399

    Article  PubMed  Google Scholar 

  87. Uchida H, Suzuki T, Takeuchi H et al (2011) Low dose vs. standard dose of antipsychotics for relapse prevention in schizophrenia: meta-analysis. Schizophr Bull 37(4):788–799

    Article  PubMed  Google Scholar 

  88. Suzuki T, Remington G, Arenovich T et al (2011) Time course of improvement with anti­psychotic medication in treatment-resistant schizophrenia. Br J Psychiatry 199(4):275–280

    Article  PubMed  Google Scholar 

  89. Csernansky JG, Mahmoud R, Brenner R et al (2002) A comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia. N Engl J Med 346(1):16–22

    Article  PubMed  CAS  Google Scholar 

  90. Rosenheck RA, Krystal JH, Lew R et al (2011) Long-acting risperidone and oral antipsychotics in unstable schizophrenia. N Engl J Med 364(9):842–851

    Article  PubMed  CAS  Google Scholar 

  91. Suzuki T (2011) Which rating scales are regarded as ‘the standard’ in clinical trials for schizophrenia? A critical review. Psychopharmacol Bull 44(1):18–31

    PubMed  Google Scholar 

  92. Suzuki T, Remington G, Mulsant BH et al (2012) Defining treatment-resistant schizophrenia and response to antipsychotics: a review and recommendation. Psychiatry Res 197(1-2):1–6

    Google Scholar 

  93. Stern RG, Schmeidler J, Davidson M (1997) Limitations of controlled augmentation trials in schizophrenia. Biol Psychiatry 42(2):138–143

    Article  PubMed  CAS  Google Scholar 

  94. Suzuki T, Takeuchi H, Nakajima S et al (2010) Magnitude of rater differences in assessment scales for schizophrenia. J Clin Psychopharmacol 30(5):607–611

    Article  PubMed  Google Scholar 

  95. Zhu B, Ascher-Svanum H, Faries DE et al (2008) Cost of antipsychotic polypharmacy in the treatment of schizophrenia. BMC Psychiatry 8:19

    Article  PubMed  Google Scholar 

  96. Stahl SM, Grady MM (2006) High-cost use of second-generation antipsychotics under California’s Medicaid program. Psychiatr Serv 57(1):127–129

    Article  PubMed  Google Scholar 

  97. Kinon BJ, Kane JM, Johns C et al (1993) Treatment of neuroleptic-resistant schizophrenic relapse. Psychopharmacol Bull 29(2):309–314

    PubMed  CAS  Google Scholar 

  98. Seeman P (2011) All roads to schizophrenia lead to dopamine super sensitivity and elevated dopamine D2(high) receptors. CNS Neurosci Ther 17(2):118–132

    Article  PubMed  CAS  Google Scholar 

  99. Remington G, Seeman P, Feingold A et al (2011) “Extended” antipsychotic dosing in the maintenance treatment of schizophrenia: a double-blind, placebo-controlled trial. J Clin Psychiatry 72(8):1042–1048

    Article  PubMed  Google Scholar 

  100. Mizuno Y, Bies RR, Remington G et al (2012) Dopamine D2 receptor occupancy with risperi­done or olanzapine during maintenance treatment of schizophrenia: a cross-sectional study. Prog Neuropsychopharmacol Biol Psychiatry 37(1):182–187. doi:10.1016/j.pnpbp.2011.12.013

  101. Suzuki T, Uchida H, Takeuchi H et al (2005) Simplifying psychotropic medication regimen into a single night dosage and reducing the dose for patients with chronic schizophrenia. Psychopharmacology (Berl) 181(3):566–575

    Google Scholar 

  102. Moriguchi S, Bies RR, Remington G et al (In Press) Estimated Dopamine D2 Receptor Occupancy and Remission in Schizophrenia: Analysis of the CATIE Data. J Clin Psychopharmacol

    Google Scholar 

  103. Takeuchi H, Suzuki T, Uchida H et al (2012) Antipsychotic treatment for schizophrenia in the maintenance phase: a systematic review of the guidelines and algorithms. Schizophr Res 134(2–3):219–225

    Article  PubMed  Google Scholar 

  104. Fischer-Barnicol D, Lanquillon S, Haen E et al (2008) Typical and atypical antipsychotics—the misleading dichotomy. Results from the Working Group ‘Drugs in Psychiatry’ (AGATE). Neuropsychobiology 57(1–2):80–87

    Article  PubMed  CAS  Google Scholar 

  105. Krivoy A, Malka L, Fischel T et al (2011) Predictors of clozapine discontinuation in patients with schizophrenia. Int Clin Psychopharmacol 26(6):311–315

    Article  PubMed  Google Scholar 

  106. Pai NB, Laidlaw M, Vella SC (2012) Augmentation of clozapine with another pharmacological agent: treatment for refractory schizophrenia in the ‘real world’. Acta Psychiatr Scand Mar 20. doi:10.1111/j.1600-0447.2012.01854.x. [Epub ahead of print]

  107. Honer WG, Thornton AE, Chen EY et al (2006) Clozapine alone versus clozapine and risperidone with refractory schizophrenia. N Engl J Med 354(5):472–482

    Article  PubMed  CAS  Google Scholar 

  108. Friedman JI, Lindenmayer JP, Alcantara F et al (2011) Pimozide augmentation of clozapine in patients with schizophrenia and schizoaffective disorder unresponsive to clozapine monotherapy. Neuropsychopharmacology 36(6):1289–1295

    Article  PubMed  CAS  Google Scholar 

  109. López de Torre A, Lertxundi U, Hernández R, Medrano J (2012) Antipsychotic poly­pharmacy: a needle in a haystack? Gen Hosp Psychiatry 34(4):423–432

    Google Scholar 

  110. Aggarwal NK, Sernyak MJ, Rosenheck RA (2012) Prevalence of concomitant oral anti­psychotic drug use among patients treated with long-acting, intramuscular, antipsychotic medications. J Clin Psychopharmacol 32(3):323–328

    Article  PubMed  CAS  Google Scholar 

  111. Stahl SM (2012) Antipsychotic polypharmacy: never say never, but never say always. Acta Psychiatr Scand 125(5):349–351

    Article  PubMed  Google Scholar 

  112. Tani H, Uchida H, Suzuki T, Fujii Y, Mimura M (In Press) Interventions to reduce antipsychotic polypharmacy: A systematic review. Schizophr Res

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Neuropsychiatry, Keio University School of Medicine, Tokyo, Japan

    Takefumi Suzuki M.D., Ph.D., Hiroyuki Uchida M.D., Ph.D. & Masaru Mimura M.D., Ph.D.

  2. Inokashira Hospital, Tokyo, Japan

    Takefumi Suzuki M.D., Ph.D.

  3. Department of Neuropsychiatry, Kyorin University School of Medicine, Tokyo, Japan

    Koichiro Watanabe M.D., Ph.D.

Authors
  1. Takefumi Suzuki M.D., Ph.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Hiroyuki Uchida M.D., Ph.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Koichiro Watanabe M.D., Ph.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Masaru Mimura M.D., Ph.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Takefumi Suzuki M.D., Ph.D. .

Editor information

Editors and Affiliations

  1. Sha'ar Menashe Mental Health Center, Hadera, 38814, Israel

    Michael S. Ritsner

Rights and permissions

Reprints and permissions

Copyright information

© 2013 Springer Science+Business Media Dordrecht

About this chapter

Cite this chapter

Suzuki, T., Uchida, H., Watanabe, K., Mimura, M. (2013). Antipsychotic Polypharmacy in Schizophrenia. How to Counteract This Common Practice?. In: Ritsner, M. (eds) Polypharmacy in Psychiatry Practice, Volume II. Springer, Dordrecht. https://doi.org/10.1007/978-94-007-5799-8_6

Download citation

Publish with us

Policies and ethics

Search

Navigation